4/26
04:06 pm
gild
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock [Yahoo! Finance]
Low
Report
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock [Yahoo! Finance]
4/25
12:27 am
gild
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down [Yahoo! Finance]
Low
Report
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down [Yahoo! Finance]
4/24
08:07 pm
gild
Gilead's Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD [Yahoo! Finance]
Low
Report
Gilead's Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD [Yahoo! Finance]
4/23
01:37 pm
gild
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now [Yahoo! Finance]
Low
Report
Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now [Yahoo! Finance]
4/22
04:05 pm
gild
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
Low
Report
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
4/21
08:13 pm
gild
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? [Yahoo! Finance]
Low
Report
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? [Yahoo! Finance]
4/20
04:00 pm
gild
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]
Low
Report
Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]
4/20
09:19 am
gild
Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]
Low
Report
Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]
4/17
02:07 pm
gild
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]
Low
Report
Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]
4/17
12:43 pm
gild
Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]
Low
Report
Jim Cramer on Gilead Sciences: “I'd Hold On to It” [Yahoo! Finance]
4/17
09:48 am
gild
Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a "neutral" rating on the stock.
4/17
08:30 am
gild
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Low
Report
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
4/16
11:26 am
gild
Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says [Yahoo! Finance]
Low
Report
Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says [Yahoo! Finance]
4/16
08:17 am
gild
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer [Yahoo! Finance]
Low
Report
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer [Yahoo! Finance]
4/15
08:12 pm
gild
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? [Yahoo! Finance]
Low
Report
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition? [Yahoo! Finance]
4/15
07:26 pm
gild
Lightning Round: Nokia still has room to run [CNBC]
Low
Report
Lightning Round: Nokia still has room to run [CNBC]
4/14
10:25 pm
gild
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today [Yahoo! Finance]
Low
Report
Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today [Yahoo! Finance]
4/14
12:00 pm
gild
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
Low
Report
PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
4/13
10:14 pm
gild
Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing [Yahoo! Finance]
Low
Report
Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing [Yahoo! Finance]
4/13
01:18 pm
gild
Gilead Sciences (GILD) had its price target raised by Citigroup Inc. from $156.00 to $165.00. They now have a "buy" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target raised by Citigroup Inc. from $156.00 to $165.00. They now have a "buy" rating on the stock.
4/10
11:14 am
gild
Gilead Sciences (GILD) had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an "overweight" rating on the stock.
4/10
09:49 am
gild
Gilead Sciences (GILD) had its price target lowered by Cantor Fitzgerald from $155.00 to $115.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target lowered by Cantor Fitzgerald from $155.00 to $115.00. They now have an "overweight" rating on the stock.
4/9
11:47 am
gild
Buy These 3 Health Care Mutual Funds for a Volatile Market [Yahoo! Finance]
Low
Report
Buy These 3 Health Care Mutual Funds for a Volatile Market [Yahoo! Finance]
4/9
08:51 am
gild
Gilead price target raised to $155 from $152 at Truist [Yahoo! Finance]
Low
Report
Gilead price target raised to $155 from $152 at Truist [Yahoo! Finance]
4/9
08:43 am
gild
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE [Yahoo! Finance]
Low
Report
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE [Yahoo! Finance]